Current
30.3×
5-Year Average
48.3×
All-Time High
223.6×
All-Time Low
19.8×
P/FCF Ratio daily chart for Bio-Techne (TECH)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Bio-Techne (TECH) from 2002 to 2025
| 2025 | $7.97B | $256.55M | 31.1× | -16.8× | |
| 2024 | $11.30B | $236.10M | 47.9× | -11.6× | |
| 2023 | $12.86B | $216.15M | 59.5× | +11.0× | |
| 2022 | $13.59B | $280.36M | 48.5× | -8.4× | |
| 2021 | $17.52B | $307.86M | 56.9× | -9.0× | |
| 2020 | $10.12B | $153.47M | 65.9× | +15.2× | |
| 2019 | $7.93B | $156.21M | 50.8× | +13.5× | |
| 2018 | $5.56B | $149.43M | 37.2× | +3.0× | |
| 2017 | $4.39B | $128.27M | 34.2× | +1.2× | |
| 2016 | $4.20B | $126.97M | 33.1× | +2.4× | |
| 2015 | $3.66B | $119.45M | 30.6× | +2.8× | |
| 2014 | $3.42B | $122.94M | 27.8× | +2.5× | |
| 2013 | $2.57B | $101.11M | 25.4× | +2.8× | |
| 2012 | $2.73B | $120.73M | 22.6× | -2.4× | |
| 2011 | $3.09B | $123.56M | 25.0× | +5.1× | |
| 2010 | $2.13B | $106.62M | 20.0× | -2.7× | |
| 2009 | $2.38B | $104.77M | 22.7× | -7.5× | |
| 2008 | $2.99B | $98.95M | 30.2× | +2.8× | |
| 2007 | $2.26B | $82.43M | 27.4× | +2.6× | |
| 2006 | $2.01B | $80.99M | 24.8× | -3.5× | |
| 2005 | $1.78B | $63.02M | 28.2× | -0.7× | |
| 2004 | $1.79B | $61.84M | 28.9× | -3.1× | |
| 2003 | $1.24B | $38.90M | 32.0× | -181.6× | |
| 2002 | $1.15B | $5.39M | 213.6× | — |
- 202531.1×
- 202447.9×
- 202359.5×
- 202248.5×
- 202156.9×
- 202065.9×
- 201950.8×
- 201837.2×
- 201734.2×
- 201633.1×
- 201530.6×
- 201427.8×
- 201325.4×
- 201222.6×
- 201125.0×
- 201020.0×
- 200922.7×
- 200830.2×
- 200727.4×
- 200624.8×
- 200528.2×
- 200428.9×
- 200332.0×
- 2002213.6×
About P/FCF Ratio at Bio-Techne (TECH)
Bio-Techne (TECH) P/FCF ratio is 30.3× as of June 5, 2026. The 5-year average is 48.3×. The sector median currently stands at 19.8×. The current ratio is at the 2th percentile of its own 10-year history.
Bio-Techne (TECH) historical P/FCF ratio has ranged from a low of 19.8× (2011) to a high of 223.6× (2002) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Bio-Techne P/FCF Ratio by Year
Bio-Techne P/FCF Ratio 2025: 31.1×
Bio-Techne (TECH) P/FCF ratio in 2025 was 31.1×, contracted from 47.9× the prior year.
Bio-Techne P/FCF Ratio 2024: 47.9×
Bio-Techne (TECH) P/FCF ratio in 2024 was 47.9×, contracted from 59.5× the prior year.
Bio-Techne P/FCF Ratio 2023: 59.5×
Bio-Techne (TECH) P/FCF ratio in 2023 was 59.5×, expanded from 48.5× the prior year.
Bio-Techne P/FCF Ratio 2022: 48.5×
Bio-Techne (TECH) P/FCF ratio in 2022 was 48.5×, contracted from 56.9× the prior year.
Bio-Techne P/FCF Ratio 2021: 56.9×
Bio-Techne (TECH) P/FCF ratio in 2021 was 56.9×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Bio-Techne (TECH), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Bio-Techne (TECH) Key Financials
Charts, filings, and peer comparison for every metric